TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Novo Nordisk and Eli Lilly presented early conference analyses linking GLP-1 medicines to changes in molecular measures associated with biological aging. Novo reported findings from large trial datasets, while Lilly’s tirzepatide analysis was a small, uncontrolled pilot; neither presentation establishes that the drugs slow aging or extend life.
Novo Nordisk and Eli Lilly presented early data at the Aging Research & Drug Discovery conference suggesting their GLP-1 medicines may shift molecular measures associated with biological aging. The findings connect semaglutide and tirzepatide with changes in protein-based or epigenetic aging clocks, but they do not establish that either drug slows aging, extends lifespan or should be used for that purpose.
Novo’s presentation drew on blood samples from 10,052 participants, with about half receiving a GLP-1 medicine and half placebo, measured at baseline and again months later. The company said proteomic clocks—which estimate age and mortality risk from patterns of proteins—showed lower biological-age estimates across cardiovascular outcome trials. Some changes appeared within 13 to 20 weeks and were sustained or increased over follow-up of up to 150 weeks. A heart-protein clock showed a shift equivalent to as much as four years, according to the presentation; that figure describes a clock estimate, not years of life gained.
Novo Global Project Leader for R&D Nikolaj Roed said the company had seen “improved biological age in our patients across trials and across different tissues,” describing an overall difference of around two to three years. Senior scientific director Alejandro Aguayo-Orozco said semaglutide moved molecular clocks, adding: “When you intervene with semaglutide, does it actually move the clocks in any direction? And the answer is yes.” These are company interpretations of trial analyses; the conference data do not show that clock movement itself causes better health outcomes.
Lilly vice president for aging research Kevin Duffin presented an epigenetic sub-study within SURMOUNT-5, which compares tirzepatide with semaglutide. The analysis used paired blood samples from 71 participants at baseline and week 72, with 82 subjects included after quality checks. All 15 age-unit clocks estimated less aging than the 1.38 years of chronological time elapsed, but only two clocks showed statistically significant median differences, of 1.1 and 0.7 years. Lilly said two independent laboratories generated methylation data and that results pointed in a similar direction across several measures.
Aging Clocks Are Not Health Outcomes
The presentations add a new line of investigation to an already widely studied drug class. GLP-1 medicines are used for diabetes and weight management, and the companies’ conference analyses suggest that their effects may be reflected in biological measures beyond weight and blood sugar. If future studies confirm that these shifts are reliable and tied to meaningful outcomes, researchers may have a way to test whether treatment affects processes associated with aging.
For now, biological-age clocks are indirect measures, not proof that someone will live longer or avoid age-related disease. The results should not be read as a reason for people to take these medicines for longevity. Lilly described its work as a small pilot, and the data presented do not settle whether clock changes are caused by the drugs, weight loss, other health changes, or a combination of factors.
GLP-1 receptor agonist supplements
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Two Different Evidence Sets
The companies reported different types of evidence. Novo’s findings came from proteomic analyses linked to cardiovascular outcome trials, including comparisons between people assigned to treatment and placebo. Its presentation also cited a separate model based on SELECT trial estimates and a UK real-world cohort of 19,117 people. That model projected 1.9 remaining life-years gained overall across age groups. This is a modeled estimate, not an observed survival result from the aging-clock analysis.
Lilly’s results came from a narrower, single-arm epigenetic sub-study. Participants received tirzepatide, and the analysis compared their samples at the start and at week 72; it had no placebo or control group. Lilly said 91.5% of participants were taking the 15 mg dose by week 72. The two presentations therefore cannot be treated as a direct comparison of the drugs or as equivalent evidence for a shared effect.
Biological-aging clocks use different inputs and methods. Proteomic clocks estimate age from proteins, while epigenetic clocks analyze DNA methylation patterns. Lilly said its clocks were not trained on randomized-trial or longitudinal data, and some signals were discordant. The company also noted that predicted changes in several proteins did not match direct measurements, including VCAM1, SHBG and TNFRSF1B.
“When you intervene with semaglutide, does it actually move the clocks in any direction? And the answer is yes.”
— Alejandro Aguayo-Orozco, senior scientific director at Novo Nordisk
As an affiliate, we earn on qualifying purchases.
The Clock Results Need Validation
Whether the measured shifts represent slower biological aging remains unproven. Lilly’s sub-study had a small sample, no control group and only 72 weeks of follow-up. The company said the observation period was short relative to the measurement error of some clocks, and that certain clock results did not align or remained unresolved. Two of the 15 age-unit clocks reached statistical significance; the other results should not be treated as statistically established effects.
Novo’s larger analysis also leaves questions about what the clock changes mean for individual health and long-term outcomes. The conference report does not establish that changes in proteomic age cause reduced illness or mortality. It is also unclear how much of any observed effect might be related to weight loss, improved metabolic health, or other treatment effects. Neither presentation supplies evidence that would support using GLP-1 medicines solely to slow aging.
As an affiliate, we earn on qualifying purchases.
Larger Trials Must Test the Signal
Lilly said it plans to expand the work to semaglutide and other chronic weight-management studies. The next useful evidence would come from larger studies with longer follow-up, appropriate comparison groups and repeated measures, alongside clinical outcomes that matter to patients. Researchers would also need to establish whether clock changes are reproducible across methods and whether they predict outcomes independently of weight loss and other health changes.
Until then, the conference findings remain early research signals, not a new clinical recommendation. The companies have presented a possible research direction; whether GLP-1 treatment changes the course of biological aging remains an open question.
As an affiliate, we earn on qualifying purchases.
Key Questions
Did the presentations prove GLP-1 drugs slow aging?
No. They reported changes in molecular aging-clock estimates, which are indirect measures. The data do not prove slower aging, longer life or prevention of age-related disease.
Which medicines were discussed?
Novo Nordisk presented findings involving semaglutide and GLP-1 agonists. Eli Lilly presented an epigenetic sub-study of tirzepatide from the SURMOUNT-5 trial.
How strong was Lilly’s evidence?
It was preliminary: the analysis included 71 participants with paired samples, had no placebo or control group, and followed participants for 72 weeks. Only two of 15 age-unit clocks showed statistically significant median differences.
Does the Novo life-year estimate mean patients lived longer?
No. Novo cited a model that projected 1.9 remaining life-years gained overall using trial effect estimates and a UK cohort of 19,117 people. That was a modeled projection, not an observed lifespan result from the clock analysis.
Should people take these medicines for longevity?
The conference findings do not support using GLP-1 medicines solely for longevity. Decisions about these prescription drugs should be made with a qualified health professional based on established medical indications and individual circumstances.
Source: hn
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
